Annexon, Inc. (Nasdaq: ANNX) presented data from its Phase 3 ARCHER II clinical trial for vonaprument at The Retina Society ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE